The role of genetic and epigenetic factors in tumor initiation and progression is well
documented. Histone deacetylases (HDACs), histone methyl transferases (HMTs), and DNA …

Over the last several decades, it has become clear that epigenetic abnormalities may be one
of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play …

Histone deacetylases (HDACs) are evolutionary conserved enzymes which operate by
removing acetyl groups from histones and other protein regulatory factors, with functional …

Exciting therapeutic targets are emerging from CRISPR-based screens of high mutational-
burden adult cancers. A key question, however, is whether functional genomic approaches …

Childhood high-risk neuroblastomas with MYCN gene amplification are difficult to treat
effectively. This has focused attention on tumor-specific gene dependencies that underlie …

Screening of small-molecule libraries is a productive method for identifying both chemical
probes of disease-related targets and potential starting points for drug discovery. In this …

Histone deacetylases (HDACs) are a class of enzymes that remove acetyl from the ε-N-
acetyl lysine of histones, allowing histones to wrap DNA more tightly. HDACs play an …

MYC is a master regulator of stem cell state, embryogenesis, tissue homeostasis, and aging.
As in health, in disease MYC figures prominently. Decades of biological research have …

Class I histone deacetylase (HDAC) enzymes 1, 2, and 3 organize chromatin as the catalytic
subunits within seven distinct multiprotein corepressor complexes and are established drug …

Pharmacologically difficult targets, such as MYC transcription factors, represent a major
challenge in cancer therapy. For the childhood cancer neuroblastoma, amplification of the …